Literature DB >> 2425060

Prognostic factors in stage I non-seminomatous germ-cell testicular tumors managed by orchiectomy and surveillance: implications for adjuvant chemotherapy.

P Hoskin, S Dilly, D Easton, A Horwich, W Hendry, M J Peckham.   

Abstract

Between February 1979 and March 1985, 126 patients with clinical stage I non-seminomatous germ-cell testicular tumors were entered into a surveillance study after orchiectomy. Of this group, 36 (28%) have relapsed. The prognostic significance of 13 clinical, histopathologic, and biochemical factors has been analyzed. Vascular invasion and lymphatic invasion (LI) within the primary tumor, histology, and involvement of the epididymis and rete testis were significantly associated with an increased risk of relapse. However, multiple regression analysis showed that only histology and LI were significant, independent prognostic factors. These findings provide the basis for the consideration of adjuvant chemotherapy for patients with apparent clinical stage I testicular non-seminoma who are at high risk of harboring occult metastases.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 2425060     DOI: 10.1200/JCO.1986.4.7.1031

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN: 0732-183X            Impact factor:   44.544


  10 in total

1.  Preoperative Carbohydrate Antigen 19-9: Its Neglected Role in Alpha-Fetoprotein-Negative Hepatocellular Carcinoma Patients.

Authors:  Liang-He Lu; Yong-Fa Zhang; Wei Wei; Ming Shi; Rong-Ping Guo
Journal:  J Gastrointest Surg       Date:  2017-08-24       Impact factor: 3.452

Review 2.  Treatment of clinical stage I testicular cancer and a possible role for new biological prognostic parameters.

Authors:  C Bokemeyer; M A Kuczyk; J Serth; J T Hartmann; H J Schmoll; U Jonas; L Kanz
Journal:  J Cancer Res Clin Oncol       Date:  1996       Impact factor: 4.553

3.  Cost- and risk-benefit considerations in the management of clinical stage I nonseminomatous testicular tumors.

Authors:  J Baniel; B J Roth; R S Foster; J P Donohue
Journal:  Ann Surg Oncol       Date:  1996-01       Impact factor: 5.344

4.  Iatrogenic damage to male reproductive function.

Authors:  W F Hendry
Journal:  J R Soc Med       Date:  1995-10       Impact factor: 5.344

5.  [Follow-up of testicular germ cell cancer patients: interdisciplinary evidence-based recommendations].

Authors:  M Hartmann; S Krege; R Souchon; M De Santis; S Gillessen; R Cathomas
Journal:  Urologe A       Date:  2011-07       Impact factor: 0.639

6.  Pre- and post-treatment sexual life in testicular cancer patients: a descriptive investigation.

Authors:  N Aass; B Grünfeld; O Kaalhus; S D Fosså
Journal:  Br J Cancer       Date:  1993-05       Impact factor: 7.640

7.  Epidermal growth factor receptor and epididymis invasion as prognostic biomarkers in clinical stage I testicular germ cell tumours.

Authors:  Miguel F Sanmamed; E Esteban; E Uriol; R Zarate; M Capelan; C Muriel; G Crespo; J P Berros; P Pardo-Coto; Q Perez; C Alvarez-Fernández; P Jiménez Fonseca; M Luque; A Astudillo
Journal:  J Transl Med       Date:  2017-03-20       Impact factor: 5.531

8.  How safe is surveillance in patients with histologically low-risk non-seminomatous testicular cancer in a geographically extended country with limited computerised tomographic resources?

Authors:  S D Fosså; A B Jacobsen; N Aass; A Heilo; A E Stenwig; O Kummen; N B Johannessen; G Waaler; P Ogreid; L Borge
Journal:  Br J Cancer       Date:  1994-12       Impact factor: 7.640

9.  Prediction of relapse in stage I testicular germ cell tumor patients on surveillance: investigation of biomarkers.

Authors:  João Lobo; Ad J M Gillis; Annette van den Berg; Leendert H J Looijenga
Journal:  BMC Cancer       Date:  2020-08-05       Impact factor: 4.430

Review 10.  Lymphovascular invasion and presence of embryonal carcinoma as risk factors for occult metastatic disease in clinical stage I nonseminomatous germ cell tumour: a systematic review and meta-analysis.

Authors:  Joost M Blok; Ilse Pluim; Gedske Daugaard; Thomas Wagner; Katarzyna Jóźwiak; Erica A Wilthagen; Leendert H J Looijenga; Richard P Meijer; J L H Ruud Bosch; Simon Horenblas
Journal:  BJU Int       Date:  2020-01-08       Impact factor: 5.588

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.